Floatz logo

100 assets in Metastatic Melanoma

Therapeutic assets addressing Metastatic Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cediranib
Metastatic Melanoma
M.D. Anderson Cancer CenterP2BBB (73)
Dacarbazine
Metastatic Melanoma
Shanghai Junshi Bioscience Co., Ltd.P4BBB (72)
Nivolumab
Metastatic Melanoma
Bristol-Myers SquibbP4BB (70)
TIL
Metastatic Melanoma
East Metropolitan Health Service, AustraliaP2BB (69)
Ipilimumab
Metastatic Melanoma
NYU Langone HealthP4BB (68)
Interferon Alfa-2B
Metastatic Melanoma
National Cancer Institute (NCI)P3BB (66)
Irinotecan
Metastatic Melanoma
Melanoma and Skin Cancer Trials LimitedP2BB (66)
Relatlimab
Metastatic Melanoma
Bristol-Myers SquibbP4BB (66)
Carboplatin
Metastatic Melanoma
Rapa Therapeutics LLCP3BB (65)
Bcd-217
Metastatic Melanoma
BiocadP3BB (64)
Cyclophosphamide
Metastatic Melanoma
East Metropolitan Health Service, AustraliaP3BB (64)
Encorafenib
Metastatic Melanoma
SRH Wald-Klinikum Gera GmbHP4BB (64)
Fludarabine
Metastatic Melanoma
East Metropolitan Health Service, AustraliaP3BB (64)
Prolgolimab
Metastatic Melanoma
BiocadP3BB (64)
Sargramostim
Metastatic Melanoma
Mayo ClinicP2BB (64)
Lenvatinib
Metastatic Melanoma
Yale UniversityP2B (63)
Binimetinib
Metastatic Melanoma
SRH Wald-Klinikum Gera GmbHP4B (62)
Pembrolizumab
Metastatic Melanoma
Brown UniversityP3B (62)
Prednisone
Metastatic Melanoma
National Cancer Institute (NCI)P2B (62)
Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
Metastatic Melanoma
Carman GiacomantonioP2/3B (61)
Trametinib
Metastatic Melanoma
Rina PlattnerP3B (61)
Dabrafenib
Metastatic Melanoma
Mayo ClinicP3B (60)
Docetaxel
Metastatic Melanoma
OncoC4, Inc.P2B (60)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Metastatic Melanoma
Grupo Español Multidisciplinar de MelanomaP2B (60)
Selumetinib
Metastatic Melanoma
National Cancer Institute (NCI)P2B (60)
Tucidinostat
Metastatic Melanoma
HUYABIO International, LLC.P3B (60)
Cabozantinib
Metastatic Melanoma
National Cancer Institute (NCI)P2B (59)
Ziv-Aflibercept
Metastatic Melanoma
National Cancer Institute (NCI)P2B (59)
Cobimetinib
Metastatic Melanoma
Hanmi Pharmaceutical Company LimitedP2B (58)
Lifileucel
Metastatic Melanoma
Iovance Biotherapeutics, Inc.P3B (58)
Atezolizumab
Metastatic Melanoma
National Cancer Institute (NCI)P2B (57)
Axitinib
Metastatic Melanoma
Peking University Cancer Hospital & InstituteP2CCC (55)
Ibrutinib
Metastatic Melanoma
Mayo ClinicP2CCC (55)
Nilotinib
Metastatic Melanoma
Rina PlattnerP2CCC (55)
Olaparib
Metastatic Melanoma
Dana-Farber Cancer InstituteP2CCC (55)
Tocilizumab
Metastatic Melanoma
University of Southern CaliforniaP2CCC (55)
Belapectin
Metastatic Melanoma
Providence Health & ServicesP2CCC (54)
io102-io103
Metastatic Melanoma
IO BiotechP3CCC (54)
Memantine
Metastatic Melanoma
NRG OncologyP3CCC (54)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Metastatic Melanoma
Rapa Therapeutics LLCP2CCC (53)
Belvarafenib
Metastatic Melanoma
Hanmi Pharmaceutical Company LimitedP2CCC (53)
Fianlimab
Metastatic Melanoma
Grupo Español Multidisciplinar de MelanomaP2CCC (53)
Fulvestrant
Metastatic Melanoma
UNICANCERP2CCC (53)
Teonanacatl
Metastatic Melanoma
University Health Network, TorontoP2CCC (53)
Avapritinib
Metastatic Melanoma
M.D. Anderson Cancer CenterP2CCC (51)
Decitabine
Metastatic Melanoma
Roswell Park Cancer InstituteP1/2CCC (51)
Infliximab
Metastatic Melanoma
Massachusetts General HospitalP2CCC (51)
Ngfr-Transduced Autologous T Lymphocytes
Metastatic Melanoma
M.D. Anderson Cancer CenterP1/2CCC (51)
Proleukin
Metastatic Melanoma
University of LouisvilleP2CCC (51)
Rigosertib
Metastatic Melanoma
Vanderbilt-Ingram Cancer CenterP2CCC (51)
Showing 1 to 50 of 100 assets
PreviousPage 1 of 2Next